Ignite Creation Date:
2024-05-06 @ 12:40 PM
Last Modification Date:
2024-10-26 @ 1:02 PM
Study NCT ID:
NCT03817840
Status:
COMPLETED
Last Update Posted:
2024-06-04
First Post:
2019-01-15
Brief Title:
Novel Mediators of the Lipodystrophy and Metabolic Consequences of Cushings Disease
Sponsor:
Columbia University
Organization:
Columbia University
Study Overview
Official Title:
Novel Mediators of the Lipodystrophy and Metabolic Consequences of Cushings Disease
Status:
COMPLETED
Status Verified Date:
2024-05
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
This proposal will evaluate the glucocorticoid mediated changes in body fat distribution and metabolism that occur in patients with Cushings disease The objective is to identify the mechanisms that influence both the accumulation of lipodystrophic fat and also the changes in energy expenditure and metabolism that accompany them The study is designed to determine if the high cortisol and AgRP levels in the blood of people living with Cushings syndrome either from taking steroid medications or from tumors impact body fat and metabolism by turning off brown fat which is a type of fat that increases ones metabolism
Detailed Description:
Cushings disease CD is a disorder of chronic glucocorticoid GC excess that gives rise to a constellation of metabolic comorbidities and to a distinct lipodystrophic body habitus characterized by central adiposity extremity wasting and the accumulation of supraclavicular SC and dorsocervical DC fat in the region where human brown and beige adipose tissue is known to be concentrated In spite of the recognized thermogenic capacity of select cervical adipocytes the potential impact of lipomatous alterations in this depot on energy balance and metabolism in CD is unknown To our knowledge the buffalo hump and the supraclavicular fat pads - which are a sensitive physical finding for CD have never been phenotypically characterized and the mechanisms underlying the GC mediated development of fat in these depots and the associated metabolic complications have not been explored in humans The proposed research will advance our understanding of Cushings lipodystrophy and its metabolic complications Furthermore it may lead to the identification of novel mediators and targetable pathways to attenuate the adverse effects of hypercortisolism on body composition and metabolism in CD as well as in the significant population of patients treated with chronic GCs for an array of other clinical conditions These findings may have important implications not only for those with Cushings disease but for the millions of Americans who are treated with chronic glucocorticoids for an array of clinical conditions
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
False
Is a FDA Regulated Device?:
False
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None